CHICAGO — Individuals with high-risk hepatocellular carcinoma undergoing curative-intent procedures did not experience clinically meaningful deterioration in quality of life or function after adjuvant therapy, phase 3 study results showed. Patient-reported outcomes from the randomized IMbrave050 trial presented at ASCO Annual Meeting suggest that an adjuvant regimen of atezolizumab plus…Read More
Patients report no qualityoflife issues with adjuvant regimen for highrisk liver cancer
